Cadrenal Therapeutics, Inc. (CVKD)Healthcare | Biotechnology | Ponte Vedra, United States | NasdaqCM
1.54 USD
-0.03
(-1.597%) ⇩
(Aug. 28, 2026, 4 p.m.
EDT)
After hours: 1.55 +0.01 (0.649%) ⇧ (Aug. 28, 2026, 7:30 p.m. EDT) |
Hot Take ↕ | Aug. 22, 2026, 4:53 a.m. EDT
The immediate outlook is severely clouded by a sharp downward price trend over the last two weeks, dropping from $2.03 to $1.61, which aligns with a weak statistical forecast predicting further downside in the coming month. While the long-term picture shows a resilient recovery with a +82% gain last year and a positive two-year cumulative return, the company remains in a precarious biotech phase with negative earnings, negative free cash flow, and a forward P/E that indicates no near-term profitability. The lack of any dividend history confirms this is a pure growth/speculative play. Until the Phase 3 data for CAD-1005 translates into confirmed revenue or a clear path to profitability, the investment case remains speculative rather than fundamental. |
| Model | MAE |
|---|---|
| AutoARIMA ✓ | 0.075610 |
| AutoTheta | 0.080430 |
| AutoETS | 0.345591 |
| MSTL | 0.369498 |
Forecast horizon: 45 days | Selected: AutoARIMA
| Forecast Reliability | |
|---|---|
| Score | 34% |
| H-stat | 0.16 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.001 |
| Excess Kurtosis | 0.72 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Market Cap | 4,771,831 |
| Forward P/E | -0.45 |
| Beta | 1.86 |
| Website | https://www.cadrenal.com |
| Attribute | Value |
|---|---|
| 52 Week Change | -0.873892 |
| Address1 | 822 A1A North |
| Address2 | Suite 306 |
| All Time High | 101.25 |
| All Time Low | 1.49 |
| Ask | 1.6 |
| Ask Size | 1 |
| Average Analyst Rating | 1.0 - Strong Buy |
| Average Daily Volume10 Day | 45,000 |
| Average Daily Volume3 Month | 68,730 |
| Average Volume | 68,730 |
| Average Volume10Days | 45,000 |
| Beta | 1.861 |
| Bid | 1.54 |
| Bid Size | 1 |
| Book Value | 1.321 |
| City | Ponte Vedra |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 1.54 |
| Current Ratio | 3.73 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,786,665,600 |
| Day High | 1.6 |
| Day Low | 1.5 |
| Display Name | Cadrenal Therapeutics |
| Earnings Timestamp End | 1,755,777,600 |
| Earnings Timestamp Start | 1,754,564,340 |
| Ebitda | -11,651,673 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | -0.267 |
| Enterprise Value | 3,105,956 |
| Eps Current Year | -3.915 |
| Eps Forward | -3.405 |
| Eps Trailing Twelve Months | -4.88 |
| Esg Populated | 0 |
| Exchange | NCM |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 2.3275 |
| Fifty Day Average Change | -0.78750014 |
| Fifty Day Average Change Percent | -0.33834592 |
| Fifty Two Week Change Percent | -87.3892 |
| Fifty Two Week High | 14.64 |
| Fifty Two Week High Change | -13.1 |
| Fifty Two Week High Change Percent | -0.89480877 |
| Fifty Two Week Low | 1.49 |
| Fifty Two Week Low Change | 0.049999952 |
| Fifty Two Week Low Change Percent | 0.033557016 |
| Fifty Two Week Range | 1.49 - 14.64 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,674,225,000,000 |
| Float Shares | 3,142,050 |
| Forward Eps | -3.405 |
| Forward P E | -0.45227605 |
| Free Cashflow | -8,537,432 |
| Full Exchange Name | NasdaqCM |
| Full Time Employees | 5 |
| Fullday Change | -0.0250001 |
| Fullday Change Percent | -1.59745 |
| Fullday Price | 1.55 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Gross Margins | 0.0 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.11928 |
| Held Percent Institutions | 0.09793 |
| Implied Shares Outstanding | 3,098,592 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Ipo Expected Date | 2,023-01-20 |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Last Split Date | 1,724,112,000 |
| Last Split Factor | 1:15 |
| Long Business Summary | Cadrenal Therapeutics, Inc. operates as a late-stage biopharmaceutical company that develops novel therapies for life-threatening immune and thrombotic conditions. The company is developing Tecarfarin, an oral vitamin K antagonist that is in Phase 3 clinical trial designed to prevent heart attacks, strokes, and deaths due to blood clots in patients requiring chronic anticoagulation, such as patients with left ventricular assist devices, end-stage kidney disease, and atrial fibrillation; CAD-1005, a first-in-class 12-LOX inhibitor for the treatment of heparin-induced thrombocytopenia, a deadly immune-mediated thrombotic disorder that has completed Phase 2 clinical trial; and Frunexian, a parenteral clinical-stage factor XIa inhibitor designed for use in acute hospital settings that has completed Phase 1 clinical trial. It has a collaboration agreement with Abbott Global Enterprises Limited to evaluate the efficacy and safety of Tecarfarin in patients with a left-ventricular assist device. The company was incorporated in 2022 and is headquartered in Ponte Vedra, Florida. |
| Long Name | Cadrenal Therapeutics, Inc. |
| Market | us_market |
| Market Cap | 4,771,831 |
| Market State | CLOSED |
| Max Age | 86,400 |
| Message Board Id | finmb_1793167154 |
| Most Recent Quarter | 1,782,777,600 |
| Net Income To Common | -11,543,800 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 5,583,281 |
| Number Of Analyst Opinions | 3 |
| Open | 1.56 |
| Operating Cashflow | -10,162,480 |
| Operating Margins | 0.0 |
| Payout Ratio | 0.0 |
| Phone | 904 300 0701 |
| Post Market Change | 0.00999999 |
| Post Market Change Percent | 0.64935005 |
| Post Market Price | 1.55 |
| Post Market Time | 1,787,959,806 |
| Previous Close | 1.565 |
| Price Eps Current Year | -0.39335886 |
| Price Hint | 4 |
| Price To Book | 1.1657835 |
| Profit Margins | 0.0 |
| Quick Ratio | 3.392 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | strong_buy |
| Recommendation Mean | 1.0 |
| Region | US |
| Regular Market Change | -0.0250001 |
| Regular Market Change Percent | -1.59745 |
| Regular Market Day High | 1.6 |
| Regular Market Day Low | 1.5 |
| Regular Market Day Range | 1.5 - 1.6 |
| Regular Market Open | 1.56 |
| Regular Market Previous Close | 1.565 |
| Regular Market Price | 1.54 |
| Regular Market Time | 1,787,947,201 |
| Regular Market Volume | 30,008 |
| Return On Assets | -1.25932 |
| Return On Equity | -2.7516 |
| Sand P52 Week Change | 0.20504117 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Shares Outstanding | 3,098,592 |
| Shares Percent Shares Out | 0.0182 |
| Shares Short | 65,083 |
| Shares Short Previous Month Date | 1,784,073,600 |
| Shares Short Prior Month | 55,656 |
| Short Name | Cadrenal Therapeutics, Inc. |
| Short Percent Of Float | 0.0209 |
| Short Ratio | 1.38 |
| Source Interval | 15 |
| State | FL |
| Symbol | CVKD |
| Target High Price | 17.0 |
| Target Low Price | 12.0 |
| Target Mean Price | 14.0 |
| Target Median Price | 13.0 |
| Total Cash | 2,388,135 |
| Total Cash Per Share | 0.669 |
| Total Debt | 0 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -4.88 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 5.79123 |
| Two Hundred Day Average Change | -4.2512302 |
| Two Hundred Day Average Change Percent | -0.7340807 |
| Type Disp | Equity |
| Volume | 30,008 |
| Website | https://www.cadrenal.com |
| Zip | 32,082 |